Sector
PharmaceuticalsOpen
₹2,550Prev. Close
₹2,570.55Turnover(Lac.)
₹128.35Day's High
₹2,630.95Day's Low
₹2,532.852 Week's High
₹2,880.4552 Week's Low
₹1,292.85Book Value
₹375.63Face Value
₹10Mkt Cap (₹ Cr.)
2,194.81P/E
80.62EPS
31.93Divi. Yield
0.23Y/e 31 Mar( In .Cr) | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
---|---|---|---|---|
Equity Capital | 8.51 | 8.51 | 8.51 | 8.51 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 283.88 | 259.93 | 229.07 | 194.57 |
Net Worth | 292.39 | 268.44 | 237.58 | 203.08 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Revenue | 219.35 | 208.47 | 169.42 | 134.78 |
yoy growth (%) | 5.21 | 23.04 | 25.7 | 9.32 |
Raw materials | -61.7 | -53.39 | -22.74 | -23.31 |
As % of sales | 28.12 | 25.61 | 13.42 | 17.29 |
Employee costs | -39.11 | -33.45 | -37.15 | -22.28 |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Profit before tax | 53.25 | 60.06 | 41.22 | 43.7 |
Depreciation | -9.5 | -9.63 | -9.38 | -5.45 |
Tax paid | -13.73 | -14.88 | -10 | -13.14 |
Working capital | 22.11 | 12.78 | 30.69 | 13.13 |
Other operating items |
Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 5.21 | 23.04 | 25.7 | 9.32 |
Op profit growth | -15.86 | 36.55 | 6.29 | 20.73 |
EBIT growth | -12.94 | 38.35 | 0.52 | 26.8 |
Net profit growth | -0.96 | 27.79 | 2.17 | 22.52 |
Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
---|---|---|---|---|---|
Gross Sales | 304.55 | 266.09 | 235.01 | 214.33 | 183.27 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 304.55 | 266.09 | 235.01 | 214.33 | 183.27 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 15.25 | 19.56 | 14.16 | 4.68 | 6.37 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,568.65 | 123.31 | 3,76,323.69 | 867.6 | 0.86 | 5,536.99 | 98.75 |
Divis Laboratories Ltd DIVISLAB | 4,519.8 | 76.17 | 1,19,994.45 | 531 | 0.66 | 2,259 | 507.93 |
Cipla Ltd CIPLA | 1,485.5 | 32.29 | 1,19,928.54 | 1,038.4 | 0.57 | 3,444.92 | 346.41 |
Zydus Lifesciences Ltd ZYDUSLIFE | 1,144.45 | 33.51 | 1,15,173.54 | 1,405.2 | 0.26 | 3,172.6 | 156.19 |
Dr Reddys Laboratories Ltd DRREDDY | 6,636 | 25.85 | 1,10,759.07 | 1,034.8 | 0.6 | 5,081.8 | 1,458.96 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Non Executive Dir.
Bhupendra V Gandhi
Non-Exec & Non-Independent Dir
Sanjiv D Gandhi
Non Executive Director
Nina Gandhi
Independent Non Exe. Director
Sandhya Patel
Independent Non Exe. Director
Ashok Bhadakal
Independent Non Exe. Director
Ameet Desai
ED / MD / CEO / Promoter
Rajiv D Gandhi
Non-Exec & Non-Independent Dir
Ravin Gandhi
Executive Director
PRIYA RAJIV GANDHI
Independent Non Exe. Director
Anil Jain
Independent Non Exe. Director
Jatin Yagneshbhai Trivedi
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Hester Biosciences Ltd
Summary
Hester Biosciences Limited is one of the leading and pioneering animal healthcare companies in India. Since its incorporation in Apr 87, the Company has been engaged in the production and distribution of vaccines and health products. Headquartered in Ahmedabad, Gujarat, the Company is currently the second-largest maker of poultry vaccines in India, having acquired strong brand equity over the years. The Company principally engages in two business verticals, namely Poultry Healthcare and Animal Healthcare. Its products are registered with several countries, and internal agencies, and have gained widespread recognition in both India and international markets. It has built a presence in several regions of Africa and in numerous nations, including Vietnam, Indonesia, Nepal, and Bangladesh. The products and services offered include over 51 vaccines and 70+ health products. In addition, it offers a vast selection of pharmaceuticals, feed supplements, and disinfectants for poultry and large animals.The Company markets and distributes veterinary and pharmaceutical products like animal health products, poultry vaccines, poultry diagnostic, laboratory kits and reagents. It markets the veterinary products of many international companies including Ghen Corporation, Japan; Maine Biological Laboratories, US; Idexx Corporation, US; International Diagnostic Systems Corporation, US; Biogal Galed Laboratories, Israel; and Kemin Europa, Belgium.The companys own production of veterinary vaccines
Read More
The Hester Biosciences Ltd shares price on N/A is Rs.₹2583.1 today.
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Hester Biosciences Ltd is ₹2197.41 Cr. as of 22 Jul ‘24
The PE and PB ratios of Hester Biosciences Ltd is 80.62 and 7.00 as of 22 Jul ‘24
The 52-week high/low is the highest and lowest price at which a Hester Biosciences Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Hester Biosciences Ltd is ₹1292.9 and ₹2975.6 as of 22 Jul ‘24
Hester Biosciences Ltd's CAGR for 5 Years at 8.77%, 3 Years at 1.81%, 1 Year at 46.36%, 6 Month at 66.42%, 3 Month at 57.89% and 1 Month at 23.49%.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.